Literature DB >> 18334285

The "metabolovirus" model of hepatitis B virus suggests nutritional therapy as an effective anti-viral weapon.

Amir Shlomai1, Yosef Shaul.   

Abstract

Hepatitis B virus (HBV) is a small DNA virus that targets the liver almost exclusively. Chronic infection with HBV might lead to severe liver-related pathologies including chronic hepatitis, cirrhosis and hepatocellular carcinoma. Based on its enhancer composition, which links nutritional signals that control hepatic glucose and fat metabolism in the liver to HBV gene expression and replication, it appears that the virus has adopted a regulatory system that is unique to the major hepatic metabolic genes. This unique virus-host interaction, mediated by metabolic events in the liver, is designated by us the "metabolovirus model". We hypothesize that by mimicking the expression of key genes implicated in glucose homeostasis, HBV sophisticatedly exploits the host resources to ensure its persistence. Specifically, by recruiting transcription factors and coactivators common to essential hepatic metabolic genes the virus avoids a possible resistance by its host, on the one hand, and ensures a timely and proper response to changes in its environment in terms of metabolic milieu, on the other hand. Furthermore, by coupling its gene expression to the expression of hepatic metabolic genes that fluctuate during the day, we predict a fluctuating nature of HBV gene expression. This can serve the virus in its attempts to escape the host immune system in addition to other immune evading strategies adopted by the virus, such as the secretion of the e antigen. Based on our "metabolovirus model", we suggest new mechanisms to previously unexplained clinical phenomena, such as the observed diversity in disease severity between different geographical areas that differ in nutritional habits. Furthermore, given the up-regulatory effect of food deprivation on HBV gene expression and replication, we suggest that conditions of short-term starvation should be completely avoided by HBV-infected individuals, and dietary recommendations such as the ingestion of complex carbohydrates before sleep should be adopted. Thus, our hypothesis sets the stage for viral manipulation by controlling food intake, and opens additional avenues towards food or nutritional therapy as an effective anti-HBV weapon.

Entities:  

Mesh:

Year:  2008        PMID: 18334285     DOI: 10.1016/j.mehy.2007.08.032

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  15 in total

1.  Hepatitis B virus molecular biology and pathogenesis.

Authors:  R Jason Lamontagne; Sumedha Bagga; Michael J Bouchard
Journal:  Hepatoma Res       Date:  2016-07-01

2.  Role of peroxisome proliferator-activated receptor gamma coactivator 1alpha in AKT/PKB-mediated inhibition of hepatitis B virus biosynthesis.

Authors:  Caitlin R Ondracek; Alan McLachlan
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

3.  Silencing Retinoid X Receptor Alpha Expression Enhances Early-Stage Hepatitis B Virus Infection In Cell Cultures.

Authors:  Mei Song; Yinyan Sun; Wenhui Li; Ji Tian; Wenhui He; Guangwei Xu; Zhiyi Jing
Journal:  J Virol       Date:  2018-03-28       Impact factor: 5.103

4.  Limited effects of fasting on hepatitis B virus (HBV) biosynthesis in HBV transgenic mice.

Authors:  Lie Li; Claudia E Oropeza; Klaus H Kaestner; Alan McLachlan
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

5.  Clinical and virological characteristics post HBsAg seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without.

Authors:  Chia-Ming Chu; Deng-Yn Lin; Yun-Fan Liaw
Journal:  Dig Dis Sci       Date:  2012-08-18       Impact factor: 3.199

6.  Transactivation of the hepatitis B virus core promoter by the nuclear receptor FXRalpha.

Authors:  Christophe Ramière; Caroline Scholtès; Olivier Diaz; Vinca Icard; Laure Perrin-Cocon; Mary-Anne Trabaud; Vincent Lotteau; Patrice André
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

7.  GCN5 acetyltransferase inhibits PGC1α-induced hepatitis B virus biosynthesis.

Authors:  Xiaohui Tian; Fei Zhao; Zhikui Cheng; Ming Zhou; Xiaoguang Zhi; Jiafu Li; Kanghong Hu
Journal:  Virol Sin       Date:  2013-07-02       Impact factor: 4.327

8.  Risk factors associated with liver steatosis and fibrosis in chronic hepatitis B patient with component of metabolic syndrome.

Authors:  Shaohang Cai; Zejin Ou; Duan Liu; Lili Liu; Ying Liu; Xiaolu Wu; Tao Yu; Jie Peng
Journal:  United European Gastroenterol J       Date:  2018-01-16       Impact factor: 4.623

9.  Viral expression and molecular profiling in liver tissue versus microdissected hepatocytes in hepatitis B virus-associated hepatocellular carcinoma.

Authors:  Marta Melis; Giacomo Diaz; David E Kleiner; Fausto Zamboni; Juraj Kabat; Jinping Lai; Giulia Mogavero; Ashley Tice; Ronald E Engle; Steven Becker; Charles R Brown; Jeffrey C Hanson; Jaime Rodriguez-Canales; Michael Emmert-Buck; Sugantha Govindarajan; Michael Kew; Patrizia Farci
Journal:  J Transl Med       Date:  2014-08-21       Impact factor: 5.531

10.  CRTC2 enhances HBV transcription and replication by inducing PGC1α expression.

Authors:  Xiaohui Tian; Fei Zhao; Weihua Sun; Xiaoguang Zhi; Zhikui Cheng; Ming Zhou; Kanghong Hu
Journal:  Virol J       Date:  2014-02-14       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.